• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Autoimmun Characteristics and Prognostic Factors of Disease Severity in Patients With COVID-19: The Beijing Experience

tetano

Editor, Senior Moderator
J Autoimmun


. 2020 Apr 24;102473.
doi: 10.1016/j.jaut.2020.102473. Online ahead of print.
Characteristics and Prognostic Factors of Disease Severity in Patients With COVID-19: The Beijing Experience


Ying Sun[SUP] 1 [/SUP], Yanli Dong[SUP] 2 [/SUP], Lifeng Wang[SUP] 3 [/SUP], Huan Xie[SUP] 4 [/SUP], Baosen Li[SUP] 5 [/SUP], Christopher Chang[SUP] 6 [/SUP], Fu-Sheng Wang[SUP] 7 [/SUP]



Affiliations

Abstract

COVID-19 has become one of the worst infectious disease outbreaks of recent times, with over 2.1 million cases and 120,000 deaths so far. Our study investigated the demographic, clinical, laboratory and imaging features of 63 patients with COVID-19 in Beijing. Patients were classified into four groups, mild, moderate, severe and critically ill. The mean age of our patients was 47 years of age (range 3-85) and there was a slight male predominance (58.7%). Thirty percent of our patients had severe or critically ill disease, but only 20% of severe and 33% of critically ill patients had been to Wuhan. Fever was the most common presentation (84.1%), but cough was present in only slightly over half of the patients. We found that lymphocyte and eosinophils count were significantly decreased in patients with severe disease (p = 0.001 and p = 0.000, respectively). Eosinopenia was a feature of higher levels of severity. Peripheral CD4[SUP]+[/SUP], CD8[SUP]+[/SUP] T lymphocytes, and B lymphocytes were significantly decreased in severe and critically ill patients, but there was only a non-statistically significant downward trend in NK cell numbers with severity. Of note is that liver function tests including AST, ALT, GGT and LDH were elevated, and albumin was decreased. The inflammatory markers CRP, ESR and ferritin were elevated in patients with severe disease or worse. IL-6 levels were also higher, indicating that the presence of a hyperimmune inflammatory state portends higher morbidity and mortality. In a binary logistic regression model, C-reactive protein level (OR 1.073, [CI, 1.013-1.136]; p = 0.017), CD8 T lymphocyte counts (OR 0.989, [CI, 0.979-1.000]; p = 0.043), and D-dimer (OR 5.313, [CI, 0.325-86.816]; p = 0.241) were independent predictors of disease severity.

Keywords: 2019 novel coronavirus disease; COVID-19; Cytokine storm; Elevated liver enzymes; Interleukin-6; Lymphocyte subsets; Mortality; Prognosis; SARS-CoV-2.



Copyright ? 2020. Published by Elsevier Ltd.
 
Back
Top Bottom